Have you received antibodies to prevent infection if you have not mounted an antibody response to the vaccine?

The FDA gave Emergency Use Authorization to AstraZenaca's EVUSHELD in December 2021 for those who, because of immune status or medication have been vaccinated but were unable to develop antibodies (most on b cell depletion or CD20 meds) or those who are unable to receive the vaccine. Many MS centers around the US are offering it to their immunosuppressed patients. On February 24, 2022, the FDA modified its recommendations to add a second dose as soon as possible after the first since it is not as responsive to the Omicron variant as they would like to have seen.